|
GOT2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.61749999999916E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.75939000000014E-05 |
| Normal-vs-Stage2 |
4.376300E-02 |
| Normal-vs-Stage3 |
9.62929999959172E-07 |
| Normal-vs-Stage4 |
1.57130000122407E-08 |
| Stage1-vs-Stage2 |
1.433770E-04 |
| Stage1-vs-Stage3 |
1.868360E-01 |
| Stage1-vs-Stage4 |
7.999600E-03 |
| Stage2-vs-Stage3 |
3.61490000000408E-05 |
| Stage2-vs-Stage4 |
1.96180000000545E-06 |
| Stage3-vs-Stage4 |
2.113600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.53869999969447E-07 |
| Normal-vs-AfricanAmerican |
6.178800E-04 |
| Normal-vs-Asian |
3.162800E-03 |
| Caucasian-vs-AfricanAmerican |
8.530200E-01 |
| Caucasian-vs-Asian |
9.805600E-01 |
| AfricanAmerican-vs-Asian |
8.894800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.020200E-04 |
| Normal-vs-Female |
1.042490E-04 |
| Male-vs-Female |
7.443200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.72390000000122E-06 |
| Normal-vs-Age(41-60Yrs) |
3.54770000000615E-05 |
| Normal-vs-Age(61-80Yrs) |
6.043000E-01 |
| Normal-vs-Age(81-100Yrs) |
1.428210E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.562200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.404700E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.517200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.423800E-03 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.566800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.902300E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.760100E-03 |
| Classical-VS-Follicular |
2.70019995252113E-09 |
| Classical-VS-Other |
7.197800E-01 |
| Classical-VS-Normal |
3.50860000053466E-07 |
| Tall-VS-Follicular |
5.4980464625487E-12 |
| Tall-VS-Other |
5.524000E-01 |
| Tall-VS-Normal |
3.95570243227894E-11 |
| Follicular-VS-Other |
3.564100E-02 |
| Follicular-VS-Normal |
2.811900E-02 |
| Other-VS-Normal |
7.838100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.687700E-02 |
| Normal-vs-N1 |
2.20712337295481E-13 |
| N0-vs-N1 |
9.58499946079883E-11 |
|
|
